Back to News
Market Impact: 0.2
Akari Expands IP Portfolio With PCT Filing For PH1 ADC Payload
Source: Nasdaq
Healthcare & BiotechPatents & Intellectual Property
Akari Therapeutics filed a new Patent Cooperation Treaty (PCT) application covering its PH1 payload and its use in disrupting multiple cancer-driving pathways through RNA-splicing modulation. The filing strengthens the company’s intellectual-property position around its oncology platform, but does not provide clinical, financial, or commercialization updates.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
AKTX0.55
More News
- One of our most recent defensive buys cleared a hurdle and its stock jumped
- Cullinan initiates FDA filing for lung cancer drug zipalertinib
- Moderna to replace Warner Bros Discovery on Nasdaq 100
- Analysis-David Ellison’s appointment of Kreiz brings cost-cutter to Paramount-Warner Bros Discovery
- Why McKesson Stock Soared More Than 5% Higher Today
- Paramount’s new co-CEO once hired a barista he met at a cafe with no resume. His advice to Gen Z: ‘Look up and make eye contact’